Platelet rich plasma and hyaluronic acid in shoulder tendon injuries

Use of platelet rich plasma and hyaluronic acid in rotator cuff injuries

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

REBEC

Registry ID

RBR-105wyncc

Enrollment

Unknown

Registered

2021-11-12

Start date

2021-12-27

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder injuries

Interventions

Subacromial Infiltration of Platelet Rich Plasma (PRP), Hyaluronic Acid (HA) Triamcinolone (T) in patients with rotator cuff injuries. The sample size was calculated based on the SPADI, Quick-DASH and

33575

52020

6972

Eligibility

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Adults aged between 40 and 85 years, regardless of gender; clinical and radiological diagnosis of tendinopathy or partial bursal lesions <50% of the supra and infraspinatus thickness; availability of follow-up during the study period; provided voluntary written consent to participate in the study, confirmed by signing the informed consent form

Exclusion criteria

Exclusion criteria: Having other joint diseases or joint trauma, autoimmune diseases or intra-articular medication in the last 12 months; history of acute or chronic communicable diseases, including hepatitis B, hepatitis C and HIV; history of systemic bone or cartilaginous disorders; evidence of active infection or history of infection in the joint to be infiltrated in this study; comorbidity that the physician considers as a contraindication for the infiltration of platelet-rich plasma; chronic treatment with anticoagulant or immunosuppressive drugs; previous surgery (at any time) of the affected shoulder; presence of at least one of the following diseases: adhesive capsulitis, calcareous tendonitis, glenohumeral arthrosis or acromioclavicular joint disease

Design outcomes

Primary

Measure	Time frame
VSA (Visual Scale Analogic of Pain) - A lower value is expected in patients treated with Platelet Rich Plasma and with Hyaluronic Acid than in the control group.;SPADI - An improvement in the scores of this questionnaire is expected in patients undergoing treatment with Platelet Rich Plasma and with Hyaluronic Acid than in the control group.;Quick-DASH - An improvement in the scores of this questionnaire is expected in patients undergoing treatment with Platelet Rich Plasma and with Hyaluronic Acid than in the control group.	—

Measure

Time frame

VSA (Visual Scale Analogic of Pain) - A lower value is expected in patients treated with Platelet Rich Plasma and with Hyaluronic Acid than in the control group.;SPADI - An improvement in the scores of this questionnaire is expected in patients undergoing treatment with Platelet Rich Plasma and with Hyaluronic Acid than in the control group.;Quick-DASH - An improvement in the scores of this questionnaire is expected in patients undergoing treatment with Platelet Rich Plasma and with Hyaluronic Acid than in the control group.

—

Secondary

Measure	Time frame
Secondary outcomes are not expected	—

Countries

Brazil

Contacts

Public ContactPaulo Lara

phslara@gmail.com5511 3003-2442

Outcome results

None listed

Source: REBEC (via WHO ICTRP)